US FDA approves Oncology Venture’s IDE and IND for a clinical trial in ovarian cancer patients with its PARP inhibitor and biomarker 2X-121 DRP
Hoersholm, Denmark, August 27, 2018 – Oncology Venture AB (OV:ST) (“OV” or the “Company”), Oncology Venture US and Medical Prognosis Institute (MPI.ST) today announced that the US Food and Drug Administration (FDA) has accepted its Investigational Device Exemption (IDE) and its Investigational New Drug Application (IND) to begin a Phase 2 clinical trial in advanced ovarian cancer with 2X-121 -a PARP inhibitor- using it’s Drug Response Predictor – DRP® – to select patients with high likelihood of responding to the treatment. The 2X-121 DRP has a gene signature consisting of more than 400